利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.015 秒)

    Production of beta-form thiamine hydrochloride crystals
    2.
    发明公开
    Production of beta-form thiamine hydrochloride crystals 失效
    Herstellung vonβ-Form-Thiamine Hydrochlorid-Kristallen。

    公开(公告)号：EP0533103A1

    公开(公告)日：1993-03-24

    申请号：EP92115741.8

    申请日：1992-09-15

    申请人： TAKEDA CHEMICAL INDUSTRIES, LTD.

    发明人： Asogawa, Tatsuo ,  Kakiguchi, Yoshitomi ,  Izuhara, Seiji

    IPC分类号： C07D415/00 ,  A61K31/51

    CPC分类号： C07D415/00 ,  Y10S514/951 ,  Y10S514/952

    摘要： A method of producing β-form thiamine hydrochloride crystals which comprises moistening α-form thiamine hydrochloride crystals in the presence of β-form thiamine hydrochloride crystals as seed crystals and stirring the mixture and a method of producing pharmaceutical preparations containing β-form thiamine hydrochloride crystals which comprises moistening α-form thiamine hydrochloride crystals, together with a binder, with water in the presence of β-form thiamine hydrochloride crystals as seed crystals and stirring the mixture.
    β-Form thiamine hydrochloride crystals which are stable and resistant to caking and pharmaceutical preparations containing the same can be produced in a simple and easy manner.

    摘要翻译： 一种生产β型硫胺素盐酸盐晶体的方法，其包括在存在β型硫胺素盐酸盐晶体作为晶种的情况下将α型硫胺素盐酸盐晶体润湿并搅拌该混合物，以及制备含有β-甲硫氨酸盐酸盐晶体的药物制剂的方法 其包括将α型硫胺素盐酸盐晶体与粘合剂一起在存在β型盐酸硫胺素晶体作为晶种的水中搅拌并搅拌该混合物。 稳定且耐结块的β型盐酸硫胺素晶体和含有该结晶的药物制剂可以简单和容易地制备。

    Riboswitches, methods for their use, and compositions for use with riboswitches
    3.
    发明公开
    Riboswitches, methods for their use, and compositions for use with riboswitches 审中-公开
    核糖开关，它们的使用方法，从而组合物

    公开(公告)号：EP2233494A3

    公开(公告)日：2013-05-29

    申请号：EP10003657.3

    申请日：2003-09-22

    申请人： Yale University

    发明人： Breaker, Ronald ,  Nahvi, Ali ,  Sudarsan, Narasimhan ,  Ebert, Margaret S. ,  Winkler, Wade ,  Barrick, Jeffrey E. ,  Wickiser, John K.

    IPC分类号： C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  C12Q1/68 ,  C12P19/34 ,  C12N5/00 ,  C12N15/63 ,  A61K31/00 ,  C07D415/00

    CPC分类号： C12N15/113 ,  A61K31/00 ,  C07D415/00 ,  C07D473/18 ,  C07D473/34 ,  C12N15/115 ,  C12N15/67 ,  C12N2310/53

    摘要： It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural "riboswitches" (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new nonimmunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen-turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments.

    NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    4.
    发明公开
    NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
    NITRO和镀锌亚硝基化合物心血管，组合物及使用方法

    公开(公告)号：EP1670459A2

    公开(公告)日：2006-06-21

    申请号：EP04781569.1

    申请日：2004-08-20

    申请人： Nitromed, Inc.

    发明人： GARVEY, David, S. ,  LETTS, Gordon, L. ,  WORCEL, Manuel ,  GASTON, Ricky, D.

    IPC分类号： A61K31/405 ,  A61K31/44 ,  A61K31/535 ,  C07D209/04 ,  C07D221/02 ,  C07D415/00

    CPC分类号： C07D493/04 ,  C07D407/04 ,  C07K5/06026

    摘要： The invention describes novel nitrosated and/or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated cardiovascular compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at,least one cardiovascular compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; and (k) treating nephropathy. The nitrosated and/or nitrosylated cardiovascular compounds are preferably nitrosated and/or nitrosylated P-adrenergic antagonists, nitrosated and/or nitrosylated angiotensin­converting enzyme (ACE) inhibitors, nitrosated and/or nitrosylated anti-hyperlipidemic compounds, and nitrosated and/or nitrosylated antithrombotic and vasodilator compounds.

    DETERGENT COMPOSITIONS
    6.
    发明公开
    DETERGENT COMPOSITIONS 有权
    洗涤剂组合物

    公开(公告)号：EP3063146A1

    公开(公告)日：2016-09-07

    申请号：EP14793278.4

    申请日：2014-11-03

    申请人： Innospec Limited

    发明人： GILES, Matthew Robert

    IPC分类号： C07D415/00 ,  C11D1/58

    CPC分类号： C07D307/62 ,  A61K8/49 ,  A61K8/4973 ,  A61Q5/02 ,  A61Q19/10 ,  C07D415/00 ,  C11D1/10 ,  C11D1/126 ,  C11D1/14 ,  C11D1/146 ,  C11D1/58 ,  C11D1/86 ,  C11D3/28 ,  C11D3/30

    摘要： A compound of formula (I): wherein R1 is a C5 to C39 alkyl or alkenyl group and R2 is selected from (a), (b) and (c): wherein one of W, X, Y and Z is a covalent bond and the remaining groups are independently selected from H, M, SO3M and P(O)R3R4 provided at least one of W, X, Y and Z is SO3M or P(O)R3R4; each M is independently a hydrogen ion, an ammonium ion or a metal ion; A is an anion; each of R3 and R4 is independently selected from OH, OM and OR5 wherein R5 may be a C1 to C39 hydrocarbyl group or the residue of a further compound of the present invention including an R2 group of formula (a).

    摘要翻译： 其中R 1是C 5至C 39烷基或链烯基并且R 2是（c）的式（I）化合物，其中A是阴离子。

    Riboswitches, methods for their use, and compositions for use with riboswitches
    7.
    发明公开
    Riboswitches, methods for their use, and compositions for use with riboswitches 审中-公开
    Riboswitches，Verfahrenfürderen Anwendung，Zusammensetzungen damit

    公开(公告)号：EP2233494A1

    公开(公告)日：2010-09-29

    申请号：EP10003657.3

    申请日：2003-09-22

    申请人： Yale University

    发明人： Breaker, Ronald ,  Nahvi, Ali ,  Sudarsan, Narasimhan ,  Ebert, Margaret S. ,  Winkler, Wade ,  Barrick, Jeffrey E. ,  Wickiser, John K.

    IPC分类号： C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  C12Q1/68 ,  C12P19/34 ,  C12N5/00 ,  C12N15/63 ,  A61K31/00 ,  C07D415/00

    CPC分类号： C12N15/113 ,  A61K31/00 ,  C07D415/00 ,  C07D473/18 ,  C07D473/34 ,  C12N15/115 ,  C12N15/67 ,  C12N2310/53

    摘要： It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural "riboswitches" (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new nonimmunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen-turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments.

    摘要翻译： 已经发现某些天然mRNA用作代谢物敏感的遗传开关，其中RNA直接结合小的有机分子。 这种结合过程改变mRNA的构象，其通过各种不同的机制引起基因表达的改变。 这些天然“核糖开关”（通过使用各种核酸工程策略产生）的修饰版本可被用作由特异性效应子化合物控制的设计者遗传开关。 激活核糖开关的这种效应化合物在本文中称为触发分子。 天然开关是抗生素和其他小分子疗法的靶标。 此外，核糖开关的结构允许使用自然开关的实际部分来构建新的非免疫基因控制元件，例如适配子（分子识别）结构域可以与其他非天然适体（或以其它方式修饰）交换，使得 新的识别结构域由用户定义的效应子化合物引起遗传调控。 改变的开关成为治疗方案的一部分 - 开启或关闭或调节蛋白质合成。 新建的遗传调控网络可以应用于生物生物传感器，生物代谢工程和基因治疗治疗先进形式等领域。

    Verfahren zur Herstellung von Pyrimidinderivaten
    10.
    发明公开
    Verfahren zur Herstellung von Pyrimidinderivaten 失效
    Verfahren zur Herstellung von Pyrimidinderivaten。

    公开(公告)号：EP0342482A2

    公开(公告)日：1989-11-23

    申请号：EP89108309.9

    申请日：1989-05-09

    申请人： F. HOFFMANN-LA ROCHE AG

    发明人： Hengartner, Urs, Dr. ,  Moine, Gérard, Dr.

    IPC分类号： C07D415/00

    CPC分类号： C07D415/00

    摘要： Es wird ein neues Verfahren zur Herstellung von Thiamin beschrieben. Hierbei wird Grewe-Diamin mit einem Ortho­ameisensäureester erhitzt, das erhaltene Pyrimidinderivat der Formel
    mit einem Keton der Formel
    umgesetzt und die so erhaltene Verbindung der Formel
    in Thiamin übergeführt.

    摘要翻译： 描述了制备硫胺素的方法。 这使得Grewe二胺与原甲酸酯一起加热，所得的式（IMAGE）嘧啶衍生物与下式的酮反应，并将所得的式“IMAGE”化合物转化成硫胺素。